INNATE PHARMA SA ADR
WKN: A2PSSH | ISIN: US45781K2042 | Ticker-Symbol: IDDASiehe auch INNATE PHARMA SA
Frankfurt
06.02.26 | 15:25
1,410 Euro
-4,08 % -0,060
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,390 | 1,550 | 13:05 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.01. | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 07.01. | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025 | 381 | Business Wire | Regulatory News:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| 22.12.25 | Innate Pharma SA - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 22.12.25 | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025 | 342 | Business Wire | Regulatory News:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| 11.12.25 | Innate Pharma SA - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| INNATE PHARMA SA ADR Aktie jetzt für 0€ handeln | |||||
| 11.12.25 | Innate Pharma SA: Innate Pharma Releases Its 2026 Financial Calendar | 618 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today released its 2026 financial calendar:
March 26, 2026: Publication of 2025 financial... ► Artikel lesen | |
| 28.11.25 | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 28.11.25 | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025 | 562 | Business Wire | Regulatory News:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| 17.11.25 | Innate Pharma SA: Innate Pharma to Present at Jefferies Global Healthcare Conference | 342 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announces its participation in the Jefferies Global Healthcare Conference 2025. Members of... ► Artikel lesen | |
| 13.11.25 | Innate Pharma Q3 2025 slides: Lacutamab progress highlighted amid clinical advances | 1 | Investing.com | ||
| 13.11.25 | Innate Pharma reports 9M results | 1 | Seeking Alpha | ||
| 13.11.25 | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 13.11.25 | Innate Pharma SA: Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results | 412 | Business Wire | Following FDA clearance for confirmatory Phase 3 trial TELLOMAK-3, lacutamab is progressing toward Phase 3 initiation in H1 2026 and potential accelerated approval in Sézary syndrome IPH4502... ► Artikel lesen | |
| 10.11.25 | Innate Pharma: Aktie legt nach grünem Licht der FDA für Phase-3-Studie kräftig zu | 13 | Investing.com Deutsch | ||
| 10.11.25 | Innate Pharma SA: Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL | 429 | Business Wire | The planned confirmatory Phase 3 trial, TELLOMAK 3, aims to demonstrate efficacy of lacutamab in patients with Sézary syndrome (SS) and Mycosis fungoides (MF), who failed at least one prior line... ► Artikel lesen | |
| 05.11.25 | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 05.11.25 | Innate Pharma SA: Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates | 319 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the Company will hold a conference call on Thursday, November 13, 2025, at... ► Artikel lesen | |
| 23.10.25 | Lucid Capital Markets initiates coverage on Innate Pharma stock with Buy rating | 2 | Investing.com | ||
| 15.10.25 | Innate Pharma SA - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 14.10.25 | Innate Pharma SA: Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025 | 404 | Business Wire | The event will provide clinical perspectives and market outlook for lacutamab, Innate's lead proprietary product progressing towards potential accelerated approval in SS and confirmatory phase... ► Artikel lesen |
1 2 3 4 Weiter >>
61 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIVORYON THERAPEUTICS | 1,430 | -0,14 % | Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences | Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences
Halle (Saale) / Munich, Germany, January 7, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon)... ► Artikel lesen | |
| XOMA ROYALTY | 20,600 | -7,21 % | XOMA Royalty Corporation: XOMA Royalty Announces CFO Transition | EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from... ► Artikel lesen | |
| TME PHARMA | 0,065 | 0,00 % | TME Pharma NV: TME Pharma provides update on its activities | TME Pharma provides update on its activities Berlin, Germany, January 5, 2025, 08.00 CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the... ► Artikel lesen | |
| CANSINO BIOLOGICS | 3,676 | +0,49 % | CanSino Biologics Inc: Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle | HONG KONG, Aug 20, 2025 - (ACN Newswire) - In the first half of 2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies, product upgrades... ► Artikel lesen | |
| KARYOPHARM | 5,600 | +5,66 % | Cantor Fitzgerald startet Karyopharm-Bewertung mit "Overweight" | ||
| MEREO BIOPHARMA | 0,353 | -0,56 % | Mereo BioPharma Group plc - S-8, Securities to be offered to employees in employee benefit plans | ||
| KALVISTA PHARMACEUTICALS | 12,200 | -3,17 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista's Board of Directors granted six newly-hired employees inducement options to purchase an... ► Artikel lesen | |
| ADICET BIO | 5,450 | -6,98 % | XFRA 1IJ: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| ANNOVIS BIO | 2,105 | -1,41 % | Annovis Bio Inc.: Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment | MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative... ► Artikel lesen | |
| INTEGRA LIFESCIENCES | 9,450 | 0,00 % | Integra LifeSciences Holdings Corporation: Integra LifeSciences Receives FDA 510(k) Clearance for Use of the CUSA Clarity Ultrasonic Surgical Aspirator System for Cardiac Surgeries | PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, is pleased to announce the FDA 510(k) clearance... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 4,070 | +1,75 % | Neuphoria Therapeutics, Inc.: Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions | BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies... ► Artikel lesen | |
| RHYTHM PHARMACEUTICALS | 88,50 | +1,14 % | Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit | ||
| RECCE PHARMACEUTICALS | 0,318 | -8,09 % | Recce Pharmaceuticals - Recce expands US government collaborations | Recce announced that it signed a second Cooperative Research and Development Agreement (CRADA) with the US Army. This new arrangement with the US Army Institute of Surgical Research (USAISR) will study... ► Artikel lesen | |
| IGM BIOSCIENCES | 1,080 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 14.08.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 14.08.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 14.08.2025.ISIN NameCA87168M1068 SYNEX... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
INNATE PHARMA SA ADR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,060 (-4,08 %) liegt der Kurs bei 1,410 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INNATE PHARMA SA ADR finden Sie auf Wallstreet Online.